| Authors: |
Sutherland CS; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: simone.sutherland@roche.com., Schneider S; Pharma Personalized Healthcare, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Ribero VA; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Simpson A; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kokaliaris C; Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland., Scalco RS; Pharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Guittari CJ; PDMA Neuroscience and Rare Disease, Genentech, Inc., South San Francisco, CA, USA., Gorni K; PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland., De Vivo DC; Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, NY, USA., Martens WB; Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Karrer TM; Pharma Personalized Healthcare, F. Hoffmann-La Roche Ltd, Basel, Switzerland. |
